Shares of Invivyd, Inc. (NASDAQ:IVVD – Get Free Report) have received a consensus rating of “Hold” from the five analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $10.00.
IVVD has been the topic of several research analyst reports. BTIG Research restated a “buy” rating on shares of Invivyd in a research note on Monday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Invivyd in a report on Thursday, August 27th. HC Wainwright reiterated a “buy” rating on shares of Invivyd in a research note on Tuesday, September 29th. Finally, Weiss Ratings raised shares of Invivyd from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 8th.
Get Our Latest Research Report on Invivyd
Invivyd Stock Performance
IVVD stock opened at $0.51 on Wednesday. Invivyd has a 1-year low of $0.49 and a 1-year high of $3.01. The business has a fifty day moving average price of $0.71 and a 200-day moving average price of $1.08.
Invivyd (NASDAQ:IVVD – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.03. Invivyd had a negative return on equity of 62.49% and a negative net margin of 214.77%. The company had revenue of $15.45 million for the quarter, compared to analysts’ expectations of $15.04 million. On average, equities analysts predict that Invivyd will post -0.51 EPS for the current fiscal year.
Institutional Investors Weigh In On Invivyd
Several institutional investors and hedge funds have recently added to or reduced their stakes in IVVD. Goldman Sachs Group Inc. lifted its holdings in shares of Invivyd by 103.3% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,989,148 shares of the company’s stock valued at $1,731,000 after buying an additional 1,010,596 shares during the period. Empowered Funds LLC bought a new stake in shares of Invivyd in the third quarter worth $80,000. 49 Wealth Management LLC bought a new stake in shares of Invivyd in the third quarter worth $84,000. United Capital Financial Advisors LLC bought a new stake in shares of Invivyd in the second quarter worth $84,000. Finally, Bank of America Corp DE purchased a new stake in Invivyd during the second quarter valued at $311,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.
About Invivyd
Invivyd is a biotechnology company focused on developing antibody-based medicines to help prevent and treat infectious diseases, with an emphasis on COVID-19. Its work includes discovering and engineering monoclonal antibodies intended to retain activity against changing viral variants. The company’s lead product, pemivibart, is marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration authorized it for emergency use as pre-exposure prevention of COVID-19 in certain people with moderate-to-severe immune compromise who may not have an adequate response to vaccination.
See Also
- Five stocks we like better than Invivyd
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.
